Structures by: Brázda P.
Total: 11
?
Al2Co1.13H11.223O20P4
Science (2017) 355, 6321 166-169
a=8.4589(6)Å b=16.5069(5)Å c=5.0726(2)Å
α=90° β=90.086(5)° γ=90°
?
Co1.224Al2P4O20H10.954
Science (2017) 355, 6321 166-169
a=8.395(5)Å b=16.30(3)Å c=5.033(7)Å
α=90° β=90.44(11)° γ=90°
Tetrahydrate
C20H21F6N5O7\τimes4H2O
CrystEngComm (2016) 18, 21 3819
a=45.2368(4)Å b=8.2403(4)Å c=7.1817(18)Å
α=90° β=95.326(4)° γ=90°
Phase 1
C40H44F12N10O15
CrystEngComm (2016) 18, 21 3819
a=7.2124Å b=29.0912Å c=11.686Å
α=90° β=106.181° γ=90°
Phase 2
C20H21F6N5O7
CrystEngComm (2016) 18, 21 3819
a=7.21076(11)Å b=11.66322(14)Å c=15.64522(15)Å
α=99.3299(8)° β=98.8646(13)° γ=105.9897(12)°
Cu3.313Si
Cu3.313Si
Acta crystallographica Section B, Structural science, crystal engineering and materials (2017) 73, Pt 4 767-774
a=16.2448(4)Å b=16.2448(4)Å c=44.017(8)Å
α=90° β=90° γ=120°
Cu3.311Si
Cu3.311Si
Acta crystallographica Section B, Structural science, crystal engineering and materials (2017) 73, Pt 4 767-774
a=56.9800(3)Å b=56.9800(3)Å c=44.055(2)Å
α=90° β=90° γ=120°
Sofosbuvir, L-proline
C22H29F1N3O9P1,C5H9N1O2
Science (2019) 364, 6441 667-669
a=5.34Å b=19.53Å c=29.98Å
α=90.0° β=90.0° γ=90.0°